Evidence map›Paper›PMID 33487050›Full record

ArticleClinical trials (London, England)2021

Randomized controlled trial of an education-based intervention to improve medication adherence: Design considerations in the medication adherence in glaucoma to improve care study.

Jullia A Rosdahl, Aaron M Hein, Hayden B Bosworth, Sandra Woolson, Maren Olsen, Miriam Kirshner, Anna Hung, Kelly W Muir

Registry-linked trialOpen access · greenAbstract readClinical Trial Protocol
In one paragraph

Article in Clinical trials (London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03052257 (Improving Glaucoma Medication Adherence), which is not on this map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03052257 nacompletednot on this map

Improving Glaucoma Medication Adherence

TypeinterventionalSponsorVA Office of Research and DevelopmentRan2017 to 2021Enrolled200ConditionsGlaucomaArmsEducational - glaucoma, Dose monitoring and reminder, Educational - general, Dose monitoring
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Jullia A RosdahlDepartment of Ophthalmology, Duke University School of Medicine, Durham, NC, USA.
Aaron M HeinDepartment of Medicine, Duke University School of Medicine, Durham, NC, USA.ORCID 0000-0002-8867-6122
Hayden B BosworthDepartment of Medicine, Duke University School of Medicine, Durham, NC, USA.
Sandra WoolsonDurham Center of Innovation to Accelerate Discovery and Practice Transformation, Durham Veterans Affairs Health Care System, Durham, NC, USA.
Maren OlsenDurham Center of Innovation to Accelerate Discovery and Practice Transformation, Durham Veterans Affairs Health Care System, Durham, NC, USA.
Miriam KirshnerDurham Center of Innovation to Accelerate Discovery and Practice Transformation, Durham Veterans Affairs Health Care System, Durham, NC, USA.
Anna HungDurham Center of Innovation to Accelerate Discovery and Practice Transformation, Durham Veterans Affairs Health Care System, Durham, NC, USA.ORCID 0000-0002-0730-431X
Kelly W MuirDepartment of Ophthalmology, Duke University School of Medicine, Durham, NC, USA.ORCID 0000-0001-8213-7796
Duke University · USDurham VA Health Care System · US

Funding

Improving Glaucoma Medication AdherenceI01HX001893 · VA · DURHAM VA MEDICAL CENTER · PI MUIR, KELLY · 2018 to 2021
–
HSR&D Senior Research Career Scientist AwardIK6HX003161 · VA · DURHAM VA MEDICAL CENTER · PI Hayden B Bosworth · 2020 to 2026
–
HSRD VA I01 HX001893HSRD VA IK6 HX003161
6 · The paper itself

Abstract

backgroundGlaucoma treatment requires patients to follow daily, often times complex, eye drop regimens, but adherence is poor for many patients, putting them at risk for irreversible vision loss. A comprehensive approach is needed to address the challenges in the self-management of glaucoma. The purpose of this study is to improve glaucoma medication adherence in Veterans with medically treated glaucoma using an education-based intervention. METHODS/

designThis study is a single-site randomized controlled trial enrolling 200 Veterans and their companions, if companions are involved in their care. It has two arms: an intervention group and a control group. Participants in the intervention group receive an educational session with a non-physician interventionist and are provided with an AdhereTech smart bottle with the reminder functions activated. The control group is designed as an attention control such that they have a session on general eye health and are provided with a smart bottle but without the reminder functions activated. The primary outcome is the proportion of prescribed doses taken on schedule over 6 months following randomization according to the smart bottle. Secondary outcomes include intensification of glaucoma treatment, cost of intervention delivery, and cost-effectiveness of the intervention over 12 months. DISCUSSION: The education-based intervention that we are testing is comprehensive in scope, to encompass a variety of barriers to adherence that glaucoma patients encounter, but personalized to address issues facing individual patients. Particular attention was given to feasibility in the real-world setting, as the high throughput of patients and lack of reimbursement for educational encounters in ophthalmology would limit implementation of a resource-intensive intervention.

Indexed as

GlaucomaMedication AdherencePatient Education as TopicCost-Benefit AnalysisHumansOphthalmic SolutionsRandomized Controlled Trials as TopicVeteransOphthalmic SolutionsadherencecomplianceGlaucomaocular hypertensive therapy

Identifiers

PMID33487050
PMCPMC10048058
OpenAlexW3123088192

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.